Navigation Links
Vanda Presents Phase III Iloperidone Efficacy Data
Date:12/12/2007

Findings also demonstrate favorable safety and tolerability profile

ROCKVILLE, Md., Dec. 12 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that data from four Phase III efficacy and safety trials demonstrate that iloperidone, an investigational atypical antipsychotic, is associated with significantly greater improvements in the symptoms of schizophrenia versus placebo and has a favorable safety and tolerability profile. These results were included as part of the recently filed New Drug Application (NDA) for iloperidone and were presented for the first time this week at a major psychiatric congress. Posters containing the data presented will be posted on Vanda's Web site, http://www.vandapharma.com, on Thursday, December 13, 2007. The U.S. Food and Drug Administration (FDA) accepted the NDA submitted by Vanda for marketing approval on November 26, 2007.

The Phase III study conducted by Vanda evaluated the efficacy of iloperidone versus placebo in patients with schizophrenia. The study was a randomized, double-blind, placebo-controlled, multi-center, four-week inpatient study that enrolled 604 patients. Following fixed-dose titration, inpatients were randomized to receive iloperidone at 24 mg/day, ziprasidone at 160 mg/day, or placebo. Patients treated with iloperidone had significantly greater improvements in Positive and Negative Syndrome Scale-Total (PANSS-T) scores than those on placebo and had PANSS-T improvement comparable to ziprasidone.

"There is a great need for new treatment options for schizophrenia, particularly as patients often discontinue treatment due to efficacy and tolerability issues, as seen in the NIMH-funded
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
11. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015  BioElectronics Corporation (OTC Pink: BIEL), the ... three abstracts featuring the use of ActiPatch®, its novel ... th Congress of the European Pain Federation EFIC®, ... September 2015. The Company will also be exhibiting at ... Gianluca Bagnato , department clinical and experimental rheumatology from ...
(Date:8/27/2015)... Aug. 27, 2015   Americord Registry , a ... and placenta tissue banking company, announced today ... e-commerce website. This new website makes the expecting parent,s ... interactive shopping cart and checkout process. Logo ... blood banking websites make this service difficult to purchase ...
(Date:8/27/2015)... 27, 2015  Zimmer Biomet Holdings, Inc. (NYSE and ... that it will be participating in the Goldman Sachs ... Sachs offices in London on ... Founded in 1927 and headquartered in Warsaw, ... in musculoskeletal healthcare.  We design, manufacture and market orthopaedic ...
Breaking Medicine Technology:BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2Cord Blood Bank Revolutionizes Process of Online Cord Blood Banking 2
... Symmetry Medical Inc. (NYSE: SMA ), a leading ... and other medical markets, announced today that it has entered ... November 3, 2010.  The credit facility includes an "accordion feature" ... million. The credit facility has a term of five years. ...
... Nov. 3, 2010 Aethlon Medical, Inc. (OTC ... in developing therapeutic filtration devices to address infectious ... present tomorrow at the at the Singular Research ... Los Angeles. (Photo:   http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b ) ...
Cached Medicine Technology:Symmetry Medical Closes $200 Million Credit Facility 2Symmetry Medical Closes $200 Million Credit Facility 3Aethlon Medical to Present at the Singular Research Fifth Annual 'Best of the Uncovereds Conference' 2Aethlon Medical to Present at the Singular Research Fifth Annual 'Best of the Uncovereds Conference' 3Aethlon Medical to Present at the Singular Research Fifth Annual 'Best of the Uncovereds Conference' 4
(Date:8/27/2015)... ... ... About 10 percent of mothers experienced chronic, persistent depressive ... than 1,800 people, displacing hundreds of thousands and causing widespread damage estimated at ... most people don’t develop persistent depression after a major disaster like that, a ...
(Date:8/27/2015)... ... ... The Naderi Center is proud to announce that its own Dr. Jessica ... fat. The first and only Food and Drug Administration (FDA) approved treatment for ... only Board Certified surgeon in the D.C., Maryland, Virginia area to offer this innovative, ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... its Krames Patient Education content is ICD-10 ready and available to all clients. ... new ICD-10 code sets, which are more targeted and return a more comprehensive ...
(Date:8/27/2015)... ... 2015 , ... Zensah®, the premium athletic compression company, is ... in the Women’s Tennis Association (WTA). Glushko competes in tennis tournaments around the ... a focus on technology and comfort, Zensah® has developed compression gear to help ...
(Date:8/27/2015)... ... ... In addition to its existing Doctor of Philosophy in Leadership and Doctor ... main campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor of Nursing ... for the highest level of clinical nursing practice. , “Our vision is to ...
Breaking Medicine News(10 mins):Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2
... under the Revised National TB Control Programme (RNTCP) aims ... treatment and diagnostic services to all tuberculosis patients. It ... HIV-positive people are more prone to contracting tuberculosis. Hence ... plan to tackle this issue and multi-drug resistant cases. ...
... and minds of various people world over. But now it ... detox products are to be investigated by the British government. ... attention to some of their medical claims. , ,The ... based on investigations by Real Story's Doctors on a Detox ...
... attempting of suicide is high among the children of men ... the University of British Columbia and several other institutions in ... working or had worked at sawmills in British Columbia - ... ,They collected data on the men's history of employment, their ...
... for calming the nervous, can act otherwise leading ... ,Substances like diphenhydramine, which can be ... says Ursula Sellerberg, spokeswoman for the Federal Organization ... ,Diazepam, the main ingredient in valium, can ...
... new studies, researchers claim that more people could be ... cow disease than previously thought after new evidence emerged ... developing. // According to the scientists from Edinburgh a ... to pass through blood transfusions and surgical instruments, can ...
... market in Norwich is a non-referral drop-in-center aimed at people, ... after its fallen apart. // Founded in 1994, the centre ... mental health charity Rethink. The centre will be launching an ... and shallowness, that follows mental illness. ,The place is ...
Cached Medicine News:Health News:India to Implement National Action Plan against TB-HIV 2Health News:Mad Cow Disease – Worst Is Yet To com 2Health News:Bridging People’s lives, Post Upheava 2
... is suspected, every minute counts. ... allows rapid determination of the ... a single whole blood sample. ... within minutes - saving you ...
... Endoscopic cases it is extremely popular to combine ... Light. This combination affords the surgeon optimal ... an uncomfortable pose. The Dual Light System ... System. As such the light can be ...
... offers all the performance of a major surgical ... use in Outpatient Settings, Minor Procedure Rooms, C-Section, ... single lights either side of the OR table ... General OR when combining Flat Screen LCD Monitors ...
A Western Blot Immunassay for the detection of antibodies to primarily anti-myelin associated glycoproteins (anti-MAG) and other glycolipid autoantibodies in human serum....
Medicine Products: